Acnex filed in Europe
The marketing authorization application for Acnex (clindamycin with tretinoin) has been submitted to the European regulatory authorities. Acnex is a new product for treatment of mild to severe acne vulgaris. It’s patented and formulated as a once-daily gel. More than 4,000 patients have been included in clinical studies.
“Acnex has the potential to become a leading product in Meda’s portfolio. The product has become a strong brand on the US market. Acnex is a well documented product that is very effective and well tolerated. The product will strengthen Meda’s European position in dermatology” , said Anders Lönner, CEO of Meda AB.
The marketing authorization application covers 29 countries using a decentralised procedure (DCP). Registration in Russia, Turkey and the CIS countries will follow. More than 30 million patients suffer from mild to severe acne in the Meda markets.
For further inquiries, please contact:
Anders Larnholt, Vice President Corporate Development & IR ph: 46 709-458 878
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se .
This press release is not an offer to sell or a solicitation to buy shares in Meda. This press release also contains certain forward-looking statements with respect to certain future events and Meda’s potential financial performance. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts, and may sometimes include words such as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”, “forecast”, “believe” or other words of similar meaning. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to a number of risks and uncertainties. In the event such risks or uncertainties materialize, Meda’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Meda’s ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Meda AB’s interim or annual reports, prospectuses or press releases. Listeners and readers are cautioned that no forward-looking statement is a guarantee of future performance and that actual result could differ materially from those contained in the forward-looking statements. Meda does not intend, nor undertakes, to update any such forward looking statements.